ArticleAnnals of translational medicine2022

Twenty-eight months progression-free survival after pyrotinib therapy for HER2-positive recurrent ovarian clear cell carcinoma: a case report.

Jing Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.